Stock Price & Analysis

Based on the current market data and technical indicators, VTRS stock is showing bearish signals with RSI at 27.29 indicating oversold conditions, but the stock's downward momentum and recent price action suggest waiting for a clear reversal signal before buying.

Technical Analysis The stock is currently trading at $10.62, below its 20-day moving average of $11.21, indicating a bearish trend. The MACD at -0.34 suggests continued downward momentum.

Fundamental Analysis Viatris has underperformed the broader market significantly, dropping 12.5% YTD in 2025 compared to the S&P 500's 2.7% rise. The company's recent earnings showed mixed results, though it did surpass Wall Street's expectations in Q3 2024 with revenue of $3.75 billion.

Analyst Perspective Piper Sandler maintains a Neutral rating with a price target of $14, suggesting potential upside but emphasizing the need for clinical/regulatory success on innovative brand assets for multiple expansion. The consensus rating remains "Hold" with mixed analyst recommendations.

Conclusion Given the technical weakness and despite the oversold conditions, it would be prudent to wait for signs of price stabilization before initiating new positions. The stock needs to show clear reversal signals and break above immediate resistance levels for a more favorable entry point.

Based on the provided data and recent market analysis, here's the price prediction for VTRS stock in 2025:

VTRS stock is expected to reach $13.17 by mid-2025, representing a 20.9% upside from current levels, driven by strong earnings performance and potential clinical success with innovative brand assets. The stock could potentially hit $15 in an optimistic scenario, offering a 37.7% upside, supported by the company's solid revenue growth and strategic expansion into new therapeutic areas. However, current technical indicators showing RSI at 27.29 suggest the stock is oversold, which could lead to a short-term bounce from current levels around $10.62.

The S1 support level for VTRS Stock is $10.63 ,The R1 resistant level for VTRS Stock is $11.38.

As of the end of day on 2025-02-11, the price of VTRS Stock was $10.6.

The target price for VTRS Stock according to analyst rating is 13.67, with the highest price target at 15.00 and the lowest at 12.00. Analysts have a Hold rating on VTRS Stock overall.

The market cap of VTRS is $12.7B.

Based on the current valuation metrics and market data, VTRS is not overvalued at its current price of $10.62. The stock trades at attractive multiples with EV/EBITDA of 6.67x and P/S ratio of 0.93x in Q3 2024, indicating reasonable valuation levels compared to industry standards. Recent analyst actions support this view, with Piper Sandler raising the price target to $14, suggesting approximately 32% upside potential from current levels. The stock has underperformed the broader market with a -8.1% return over the past 52 weeks compared to S&P 500's +21.8% gain, suggesting potential for mean reversion. The company's solid Q3 2024 earnings beat and 2% projected revenue growth on a divestiture-adjusted basis further support the stock's current valuation.

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Based on the available data and market analysis, here's the price prediction for VTRS stock by 2030:

VTRS stock is projected to reach $18-20 by 2030, driven by the company's strategic expansion in innovative brand assets and sustainable healthcare solutions. The company's strong market position in generic pharmaceuticals and over-the-counter products, combined with its $13.2 billion market cap and solid revenue growth projections, supports this target. Recent analyst ratings and price targets showing a 20.9% upside potential from current levels further validate this long-term growth trajectory.

VTRS has a total of 38000 employees.